Biotech Scan

Scan

Biotech Scan

raw scan snapshot — prices as of scan date, not live 27 rows · screens, not recommendations superseded by2026-04-26-biotech-scanported fromresearch/classic/scans/_archive/2026-02-22-biotech-scan.mdscan slugbiotech-scansource typescan-archive

Biotech rotation in progress — ALNY recovered from RSI 25 to 49, MRNA surged +18% in 7 days, LEGN still collapsed at RSI 8. Gene editing broadly weak. Large pharma (LLY, GILD, BIIB) cooling from overbought levels.


Quick Snapshot

Signal Reading
Overall 🟡 MIXED — Recovery underway in mRNA/RNAi, gene editing lagging, large pharma pulling back
Key insight MRNA +18% 7D recovery trade live; LEGN RSI 8 still collapsed (2nd week); LLY -3% 7D as GLP-1 trade cools

Price Table (Validated 2026-02-22)

Stock Price RSI SMA20 vs SMA 7D 30D Signal
CRSP $53.46 58 $51.66 +3.5% +0.7% -2.3% 🟡 Neutral
BEAM $27.92 38 $28.79 -3.0% +2.3% -21.2% 🟡 Weak
EDIT $1.76 35 $1.96 -10.2% -2.8% -20.7% 🔴 Breakdown
NTLA $12.64 46 $12.82 -1.4% +6.5% -9.9% 🟡 Recovering
ALNY $336.19 49 $336.99 -0.2% +6.9% -8.0% 🟡 Recovering
LEGN $17.20 8 $19.40 -11.3% +3.2% -27.1% 🔴 Capitulation
MRNA $49.87 67 $44.23 +12.8% +18.1% +0.1% 🟠 Near Overbought
BNTX $110.14 43 $110.69 -0.5% +4.0% -6.7% 🟡 Neutral
LLY $1,009.52 47 $1,035.59 -2.5% -2.9% -6.2% 🟡 Below SMA
GILD $151.40 63 $147.11 +2.9% -2.3% +17.3% 🟡 Cooling
BIIB $192.03 62 $185.87 +3.3% -2.3% +11.3% 🟡 Cooling

Tier Analysis

Tier 1 — Recovering / Momentum (MRNA, ALNY, NTLA)

MRNA RSI jumped from 33 to 67 in one week — +18% move likely catalyst-driven. Approaching overbought; do not chase. ALNY recovered from RSI 25 to 49 — RNAi thesis intact, back near SMA. NTLA reversed from RSI 36 to 46, +6.5% 7D. Gene editing tentative bounce forming.

Tier 2 — Stable / Holding (CRSP, BNTX, LLY, GILD, BIIB)

CRSP RSI 58 above SMA — best positioned in gene editing. BNTX neutral near SMA after +4% bounce. LLY RSI 47 but now -2.5% below SMA; GLP-1 premium compressing. GILD and BIIB cooling from RSI 72 highs — RSI retreated to 63/62, still holding above SMA. Normal decompression, not breakdown.

Tier 3 — Weak / Broken (BEAM, EDIT, LEGN)

BEAM -21% 30D, RSI 38, still below SMA — no recovery signal. EDIT -21% 30D, RSI 35, -10% below SMA — continued deterioration. LEGN RSI 8 for second consecutive week — extreme capitulation, company-specific collapse, avoid unless thesis understood.


Entry Zones

Stock Zone RSI Trigger Conviction Notes
🟡 ALNY $325-$340 RSI < 45 MEDIUM RNAi leader, recovered to SMA — watch for hold confirmation
🟡 LLY $990-$1,010 RSI < 45 MEDIUM GLP-1 king pulling back to SMA zone, long-term thesis intact
🟡 BNTX $105-$112 RSI < 40 LOW mRNA recovery play, needs catalyst
🟡 NTLA $11.50-$12.50 RSI < 40 LOW-MEDIUM Gene editing recovery, smaller position
🔴 LEGN Avoid SPECULATIVE RSI 8 two weeks running, unknown catalyst, high risk

Action Matrix

Action Stocks Why
🔒 HOLD CRSP, ALNY, GILD, BIIB Holding above SMA, recovering or stable
🔍 WATCH LLY, BNTX, NTLA Pulling back or bouncing — wait for RSI confirmation
⚠️ AVOID MRNA RSI 67, +18% 7D — do not chase, extended
⚠️ AVOID BEAM, EDIT Continued weakness, no reversal signal, -20%+ 30D
⚠️ AVOID LEGN RSI 8 (second week), broken, high risk

Key Discoveries

Discovery Implication
MRNA +18% in 7 days, RSI 33→67 Likely single catalyst — do not read as sector reversal
LEGN RSI 8 two consecutive weeks Company-specific collapse, not sector contagion
GILD/BIIB RSI cooling from 72 to 63/62 Healthy decompression, not breakdown — defensive biotech still intact
LLY now -2.5% below SMA GLP-1 premium compressing — watch $990 as next support

Open Questions

  • What drove MRNA +18% 7D? Pipeline catalyst or macro short squeeze?
  • LEGN thesis: what broke? ciltacabtagene ciloleucel competitive pressure or clinical data?
  • BEAM -21% 30D with no bounce — is base forming or continued decline?
10 events

No direct external sources are attached to this read.